Novartis Inks World-First Pact With NHS England For Inclisiran
Tackling Challenge Of Cardiovascular Disease
The innovative collaboration should accelerate access to the first-in-class cholesterol lowering drug acquired with The Medicines Company buy.
You may also be interested in...
A price has finally been agreed for Novartis's small interfering RNA therapy and over the next three years, NHS England now expects to treat about 300,000 patients at high risk of a second cardiovascular event with inclisiran.
A landmark population-level agreement between Novartis and the National Health Service for the gene silencing therapy Leqvio is now being implemented following the thumbs up from health technology assessment body NICE.
The company has said coverage under medical benefit could mean $0 copays for many patients, potentially overcoming a hurdle to uptake in the biologic cholesterol market.